<p>纽约，2026 年 1 月 14 日（全球新闻稿）——Psyence Biomedical Ltd.（纳斯达克：PBM）（“Psyence BioMed” 或 “公司”）今天宣布其 1 股合并为 6.25 股的股份合并（反向股票拆分）的生效日期。在 2025 年 4 月 16 日举行的特别股东会议上，股东批准了一项特别决议，授权董事会在下次年度股东大会之前的任何时间实施最多 1 股合并为 50 股的股份合并，具体的时间和合并比例由董事会自行决定。经过这一批准，公司董事会最初授权了 1 股合并为 7.97 股的合并比例，并于 2025 年 5 月 5 日实施。2025 年 12 月 4 日，董事会批准了第二次股份合并，比例为 1 股合并为 6.25 股。</p>
<p>公司的普通股预计将在 2026 年 1 月 20 日市场开盘时以合并后的基础开始交易。合并后，公司的普通股将继续在纳斯达克资本市场以 “PBM” 符号交易，新的 CUSIP 号码为 74449F407。</p>
<p>在合并生效时，每 6.25 股已发行和流通的公司股份将自动合并为 1 股已发行和流通的普通股。公司的未到期认股权证和其他股权工具的股份数量及行使价格也将根据各自条款按比例调整。截至 2026 年 1 月 14 日，公司已发行和流通的普通股为 6,388,604 股。合并后，公司将有 1,022,177 股已发行和流通的普通股。</p>
<p>合并过程中不会发行任何零碎股份。合并产生的任何零碎股份如果小于半股，将向下舍入到最接近的整股；如果至少为半股，则向上舍入到最接近的整股。合并对所有股东的影响是统一的，不会改变任何股东在公司的百分比权益，除了因零碎股份处理而产生的微小调整。股份合并在注册股东层面进行。通过经纪人、银行或其他代理人（即以 “街名” 持有）的股东被视为实益持有人，可能会根据其经纪人、银行或代理人的程序，经历合并在其账户中反映的延迟。</p>
<p>Continental Stock Transfer &amp; Trust Company 作为合并的交换代理和转让代理。以账面形式或通过经纪账户持有股份的股东无需采取任何行动。实益持有人被鼓励与其经纪人、银行或保管人联系，询问有关股份合并影响的任何问题。</p>
<p><strong>关于 Psyence BioMed</strong></p>
<p>Psyence Biomedical Ltd.（纳斯达克：PBM）是少数几家专注于迷幻药物治疗的多资产垂直整合生物制药公司之一。它是第一家专注于开发自然来源（非合成）的裸盖菇素和伊波加因基础的迷幻药物的生命科学生物技术公司，并在纳斯达克上市。我们致力于解决未满足的心理健康需求。我们承诺采用基于证据的方法，开发安全、有效且获得 FDA 批准的自然来源迷幻治疗，适用于广泛的心理健康障碍。</p>
<p><strong>Psyence Biomedical Ltd.的联系信息</strong></p>
<p>电子邮件：ir@psyencebiomed.com</p>
<p>媒体咨询：media@psyencebiomed.com</p>
<p>一般信息：info@psyencebiomed.com</p>
<p><strong>投资者联系：</strong></p>
<p>Michael Kydd</p>
<p>投资者关系顾问</p>
<p>michael@psyencebiomed.com</p>
<p><strong>前瞻性声明</strong></p>
<p>本通讯包含 1995 年《私人证券诉讼改革法》所定义的 “前瞻性声明”。此类声明包括但不限于关于未来财务和运营结果、我们的计划、目标、期望和意图的声明，涉及未来的运营、产品和服务；以及其他通过 “可能导致”、“预计将”、“将继续”、“预计”、“估计”、“相信”、“打算”、“计划”、“预测”、“展望” 或类似含义的词语来识别的声明。</p>
<p>本通讯中的前瞻性声明包括关于股份合并的时间和实施、公司普通股预计开始以合并后基础交易的时间、公司维持符合纳斯达克持续上市标准的能力、股份合并的预期影响（包括对公司普通股市场价格的影响）、新 CUSIP 号码的发行，以及对未到期认股权证和其他股权工具的调整和股份合并在经纪和其他账户中的反映的预期时间。这些声明基于当前的假设和期望，包括股份合并将如预期生效，以及公司将继续满足纳斯达克的持续上市标准。这些假设可能被证明是错误的。不能保证公司将继续维持符合纳斯达克的持续上市要求。存在许多风险和不确定性，可能导致实际结果或表现与这些前瞻性声明所表达或暗示的有实质性不同。</p>
<p>这些风险和不确定性包括但不限于：(i) 完成股份合并的延迟或挑战；(ii) 公司维持纳斯达克持续上市标准的能力；(iii) 合并后公司股价可能的波动；(iv) 监管、竞争和经济环境的变化；(v) 与公司发展计划和临床试验相关的风险；以及 (vi) 与公司股份合并的公司授权相关的风险，包括可能对授权股份合并的股东决议的有效性、解释或充分性提出质疑的索赔或诉讼的可能性。上述因素的清单并不详尽。您应仔细考虑上述因素以及在公司于 2025 年 11 月 3 日向证券交易委员会（“SEC”）提交的最终招股说明书（文件编号：333-298285）“风险因素” 部分中描述的其他风险和不确定性。</p>
<p>这些文件识别并解决了其他重要的风险和不确定性，这些风险和不确定性可能导致实际事件和结果与前瞻性声明中包含的内容有实质性差异。实际结果和未来事件可能与这些声明中预期的内容有实质性差异。此通信中的内容不应被视为任何人对此处所列前瞻性声明将会实现的陈述，或对这些前瞻性声明所设想的任何结果将会实现的陈述。您不应对前瞻性声明过度依赖，这些声明仅在作出之日有效。除法律要求外，Psyence BioMed 不打算更新这些前瞻性声明。</p>
<p>公司不对其拟议产品的医疗、治疗或健康益处做出任何声明。美国食品和药物管理局、加拿大卫生部或其他类似监管机构尚未评估关于迷幻蘑菇、迷幻蘑菇类似物或其他迷幻化合物或营养保健产品的声明。这些产品的有效性尚未通过授权的临床研究确认。无法保证迷幻蘑菇、迷幻蘑菇类似物或其他迷幻化合物或营养保健品的使用能够诊断、治疗、治愈或预防任何疾病或状况。需要进行严格的科学研究和临床试验。公司的产品候选者是实验性的，尚未获得任何监管机构的批准用于治疗任何疾病或状况，临床结果（如有）可能无法代表未来结果。任何对潜在产品的质量、一致性、有效性和安全性的引用并不意味着公司在临床试验中已验证这些内容，或公司将完成这些试验。如果公司无法获得商业化其业务所需的批准或研究，可能会对公司的业绩和运营产生重大不利影响。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UZ3hOQ00zTXpZeE5qZzJJekl5T0RVNU1UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UZ3hOQ00zTXpZeE5qZzJJekl5T0RVNU1UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGE5MjNiNGEtM2M3Zi00ZDQzLWFlZmYtODFlNDg3NjE4YmIzLTEyOTc0NjctMjAyNi0wMS0xNS1lbg==/tiny/Psyence-Biomedical-Ltd-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGE5MjNiNGEtM2M3Zi00ZDQzLWFlZmYtODFlNDg3NjE4YmIzLTEyOTc0NjctMjAyNi0wMS0xNS1lbg==/tiny/Psyence-Biomedical-Ltd-.png"/></p>

<p>Psyence Biomedical Ltd. 宣布将于 2026 年 1 月 20 日实施 1 股换 6.25 股的反向股票拆分。这是在股东批准最高 1 股换 50 股的合并比例后进行的。该公司的普通股将在纳斯达克以 “PBM” 为交易代码，并将获得新的 CUSIP 号码。合并后，股份数量将从 6,388,604 股减少至 1,022,177 股。零碎股份将进行四舍五入，股东被建议联系他们的经纪人以获取详细信息。Psyence BioMed 专注于基于迷幻药的心理健康治疗</p>

<p>NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a special resolution authorizing the Board of Directors, at any time prior to the next annual meeting of shareholders, to implement a share consolidation at a ratio of up to 1-for-50, with the exact timing and consolidation ratio to be determined in the Board’s sole discretion. Following this approval, the Company's Board of Directors initially authorized a 1-for-7.97 consolidation ratio which was implemented Monday, May 5, 2025. On December 4, 2025, the board approved a second share consolidation at a ratio of 1-for-6.25.</p>
<div class="lb-trans"><p>纽约，2026 年 1 月 14 日（全球新闻稿）——Psyence Biomedical Ltd.（纳斯达克：PBM）（“Psyence BioMed” 或 “公司”）今天宣布其 1 股合并为 6.25 股的股份合并（反向股票拆分）的生效日期。在 2025 年 4 月 16 日举行的特别股东会议上，股东批准了一项特别决议，授权董事会在下次年度股东大会之前的任何时间实施最多 1 股合并为 50 股的股份合并，具体的时间和合并比例由董事会自行决定。经过这一批准，公司董事会最初授权了 1 股合并为 7.97 股的合并比例，并于 2025 年 5 月 5 日实施。2025 年 12 月 4 日，董事会批准了第二次股份合并，比例为 1 股合并为 6.25 股。</p>
</div><p>The Company's common shares are expected to begin trading on a post-consolidated basis at the opening of the market on January 20, 2026. Following the consolidation, the Company's common shares will continue to trade under the symbol &#34;PBM&#34; on the Nasdaq Capital Market, with a new CUSIP number 74449F407.</p>
<div class="lb-trans"><p>公司的普通股预计将在 2026 年 1 月 20 日市场开盘时以合并后的基础开始交易。合并后，公司的普通股将继续在纳斯达克资本市场以 “PBM” 符号交易，新的 CUSIP 号码为 74449F407。</p>
</div><p>At the effective time of the consolidation, every 6.25 issued and outstanding shares of the Company will automatically be combined into one issued and outstanding common share. The number of shares and the exercise price of the Company's outstanding warrants and other equity instruments will also be adjusted proportionately in accordance with their respective terms. As of January 14, 2026, the Company had 6,388,604 common shares issued and outstanding. As a result of the consolidation, the Company will have 1,022,177 common shares issued and outstanding.</p>
<div class="lb-trans"><p>在合并生效时，每 6.25 股已发行和流通的公司股份将自动合并为 1 股已发行和流通的普通股。公司的未到期认股权证和其他股权工具的股份数量及行使价格也将根据各自条款按比例调整。截至 2026 年 1 月 14 日，公司已发行和流通的普通股为 6,388,604 股。合并后，公司将有 1,022,177 股已发行和流通的普通股。</p>
</div><p>No fractional shares will be issued in connection with the consolidation. Any fractional share resulting from the consolidation will be rounded down to the nearest whole share if the fraction is less than one-half of a share and rounded up to the nearest whole share if the fraction is at least one-half of a share. The consolidation affects all shareholders uniformly and will not alter any shareholder's percentage interest in the Company, except for minor adjustments resulting from the treatment of fractional shares. The share consolidation occurs at the registered shareholder level. Shareholders who hold their common shares through brokers, banks, or other nominees (i.e., in 'street name') are considered beneficial holders and may experience a delay in the reflection of the consolidation in their accounts, depending on the procedures of their broker, bank, or nominee.</p>
<div class="lb-trans"><p>合并过程中不会发行任何零碎股份。合并产生的任何零碎股份如果小于半股，将向下舍入到最接近的整股；如果至少为半股，则向上舍入到最接近的整股。合并对所有股东的影响是统一的，不会改变任何股东在公司的百分比权益，除了因零碎股份处理而产生的微小调整。股份合并在注册股东层面进行。通过经纪人、银行或其他代理人（即以 “街名” 持有）的股东被视为实益持有人，可能会根据其经纪人、银行或代理人的程序，经历合并在其账户中反映的延迟。</p>
</div><p>Continental Stock Transfer &amp; Trust Company is acting as the exchange agent and transfer agent for the consolidation. Shareholders holding their shares in book-entry form or through brokerage accounts are not required to take any action. Beneficial holders are encouraged to contact their broker, bank, or custodian with any questions regarding the effect of the share consolidation.</p>
<div class="lb-trans"><p>Continental Stock Transfer &amp; Trust Company 作为合并的交换代理和转让代理。以账面形式或通过经纪账户持有股份的股东无需采取任何行动。实益持有人被鼓励与其经纪人、银行或保管人联系，询问有关股份合并影响的任何问题。</p>
</div><p><strong>About Psyence BioMed</strong></p>
<div class="lb-trans"><p><strong>关于 Psyence BioMed</strong></p>
</div><p>Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.</p>
<div class="lb-trans"><p>Psyence Biomedical Ltd.（纳斯达克：PBM）是少数几家专注于迷幻药物治疗的多资产垂直整合生物制药公司之一。它是第一家专注于开发自然来源（非合成）的裸盖菇素和伊波加因基础的迷幻药物的生命科学生物技术公司，并在纳斯达克上市。我们致力于解决未满足的心理健康需求。我们承诺采用基于证据的方法，开发安全、有效且获得 FDA 批准的自然来源迷幻治疗，适用于广泛的心理健康障碍。</p>
</div><p><strong>Contact Information for Psyence Biomedical Ltd.</strong></p>
<div class="lb-trans"><p><strong>Psyence Biomedical Ltd.的联系信息</strong></p>
</div><p>Email: ir@psyencebiomed.com</p>
<div class="lb-trans"><p>电子邮件：ir@psyencebiomed.com</p>
</div><p>Media Inquiries: media@psyencebiomed.com</p>
<div class="lb-trans"><p>媒体咨询：media@psyencebiomed.com</p>
</div><p>General Information: info@psyencebiomed.com</p>
<div class="lb-trans"><p>一般信息：info@psyencebiomed.com</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>Michael Kydd</p>
<div class="lb-trans"><p>Michael Kydd</p>
</div><p>Investor Relations Advisor</p>
<div class="lb-trans"><p>投资者关系顾问</p>
</div><p>michael@psyencebiomed.com</p>
<div class="lb-trans"><p>michael@psyencebiomed.com</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.</p>
<div class="lb-trans"><p>本通讯包含 1995 年《私人证券诉讼改革法》所定义的 “前瞻性声明”。此类声明包括但不限于关于未来财务和运营结果、我们的计划、目标、期望和意图的声明，涉及未来的运营、产品和服务；以及其他通过 “可能导致”、“预计将”、“将继续”、“预计”、“估计”、“相信”、“打算”、“计划”、“预测”、“展望” 或类似含义的词语来识别的声明。</p>
</div><p>Forward-looking statements in this communication include statements regarding the timing and implementation of the share consolidation, the expected timing for the Company’s common shares to begin trading on a post-consolidated basis, the Company’s ability to maintain compliance with Nasdaq’s continued listing standards, the anticipated effects of the share consolidation (including on the market price of the Company’s common shares), the issuance of a new CUSIP number, and the expected timing of adjustments to outstanding warrants and other equity instruments and the reflection of the share consolidation in brokerage and other accounts. These statements are based on current assumptions and expectations, including that the share consolidation will become effective as anticipated, and that the Company will continue to meet Nasdaq’s ongoing listing standards. These assumptions may prove incorrect. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.</p>
<div class="lb-trans"><p>本通讯中的前瞻性声明包括关于股份合并的时间和实施、公司普通股预计开始以合并后基础交易的时间、公司维持符合纳斯达克持续上市标准的能力、股份合并的预期影响（包括对公司普通股市场价格的影响）、新 CUSIP 号码的发行，以及对未到期认股权证和其他股权工具的调整和股份合并在经纪和其他账户中的反映的预期时间。这些声明基于当前的假设和期望，包括股份合并将如预期生效，以及公司将继续满足纳斯达克的持续上市标准。这些假设可能被证明是错误的。不能保证公司将继续维持符合纳斯达克的持续上市要求。存在许多风险和不确定性，可能导致实际结果或表现与这些前瞻性声明所表达或暗示的有实质性不同。</p>
</div><p>These risks and uncertainties include, among others: (i) delays or challenges in completing the share consolidation; (ii) the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; (iii) potential volatility in the Company’s share price following the consolidation; (iv) changes in the regulatory, competitive, and economic landscape; (v) risks associated with the Company’s development plans and clinical trials; and (vi) risks related to the Company’s corporate authorizations for the share consolidation, including the possibility of claims or proceedings challenging the validity, interpretation or sufficiency of the shareholder resolutions authorizing the share consolidation. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.</p>
<div class="lb-trans"><p>这些风险和不确定性包括但不限于：(i) 完成股份合并的延迟或挑战；(ii) 公司维持纳斯达克持续上市标准的能力；(iii) 合并后公司股价可能的波动；(iv) 监管、竞争和经济环境的变化；(v) 与公司发展计划和临床试验相关的风险；以及 (vi) 与公司股份合并的公司授权相关的风险，包括可能对授权股份合并的股东决议的有效性、解释或充分性提出质疑的索赔或诉讼的可能性。上述因素的清单并不详尽。您应仔细考虑上述因素以及在公司于 2025 年 11 月 3 日向证券交易委员会（“SEC”）提交的最终招股说明书（文件编号：333-298285）“风险因素” 部分中描述的其他风险和不确定性。</p>
</div><p>These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.</p>
<div class="lb-trans"><p>这些文件识别并解决了其他重要的风险和不确定性，这些风险和不确定性可能导致实际事件和结果与前瞻性声明中包含的内容有实质性差异。实际结果和未来事件可能与这些声明中预期的内容有实质性差异。此通信中的内容不应被视为任何人对此处所列前瞻性声明将会实现的陈述，或对这些前瞻性声明所设想的任何结果将会实现的陈述。您不应对前瞻性声明过度依赖，这些声明仅在作出之日有效。除法律要求外，Psyence BioMed 不打算更新这些前瞻性声明。</p>
</div><p>The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company’s product candidates are investigational and have not been approved by any regulatory authority for use in the treatment of any disease or condition, and clinical results (if any) may not be indicative of future results. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.</p>
<div class="lb-trans"><p>公司不对其拟议产品的医疗、治疗或健康益处做出任何声明。美国食品和药物管理局、加拿大卫生部或其他类似监管机构尚未评估关于迷幻蘑菇、迷幻蘑菇类似物或其他迷幻化合物或营养保健产品的声明。这些产品的有效性尚未通过授权的临床研究确认。无法保证迷幻蘑菇、迷幻蘑菇类似物或其他迷幻化合物或营养保健品的使用能够诊断、治疗、治愈或预防任何疾病或状况。需要进行严格的科学研究和临床试验。公司的产品候选者是实验性的，尚未获得任何监管机构的批准用于治疗任何疾病或状况，临床结果（如有）可能无法代表未来结果。任何对潜在产品的质量、一致性、有效性和安全性的引用并不意味着公司在临床试验中已验证这些内容，或公司将完成这些试验。如果公司无法获得商业化其业务所需的批准或研究，可能会对公司的业绩和运营产生重大不利影响。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UZ3hOQ00zTXpZeE5qZzJJekl5T0RVNU1UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyNTgxNCM3MzYxNjg2IzIyODU5MTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MGE5MjNiNGEtM2M3Zi00ZDQzLWFlZmYtODFlNDg3NjE4YmIzLTEyOTc0NjctMjAyNi0wMS0xNS1lbg==/tiny/Psyence-Biomedical-Ltd-.png" alt="" original-src="https://ml.globenewswire.com/media/MGE5MjNiNGEtM2M3Zi00ZDQzLWFlZmYtODFlNDg3NjE4YmIzLTEyOTc0NjctMjAyNi0wMS0xNS1lbg==/tiny/Psyence-Biomedical-Ltd-.png"/></p>

Psyence BioMed 宣布 1 比 6.25 反向股票拆分的生效日期 | PBM 股票新闻